Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma

  • Soriano, Aroa|||0000-0001-9659-1471
  • Masanas, Marc|||0000-0002-2249-8554
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Masiá, Núria
  • París-Coderch, Laia|||0000-0003-2145-5752
  • Piskareva, Olga
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Henrich, Kai-Oliver
  • Roma, Josep|||0000-0001-7692-6123
  • Westermann, Frank
  • Stallings, Raymond L.
  • Sábado, Constantino|||0000-0003-3956-5466
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
The online version of this article (10.1007/s00018-019-03041-4) contains supplementary material, which is available to authorized users., Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, barely 2% of all genetic information. By contrast, the therapeutic potential of targeting the transcriptome, ~ 70% of the genome, remains largely unexplored. RNA therapeutics is an emerging field that widens the range of druggable targets and includes elements such as microRNA. Here, we sought to screen for microRNA with tumor-suppressive functions in neuro-blastoma, an aggressive pediatric tumor of the sympathetic nervous system that requires the development of new therapies. We found miR-323a-5p and miR-342-5p to be capable of reducing cell proliferation in multiple neuroblastoma cell lines in vitro and in vivo, thereby providing a proof of concept for miRNA-based therapies for neuroblastoma. Furthermore, the combined inhibition of the direct identified targets such as CCND1, CHAF1A, INCENP and BCL-XL could reveal new vulnerabilities of high-risk neuroblastoma.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Long Non-coding RNA PVT1 as a Prognostic and Therapeutic Target in Pediatric Cancer

  • Boloix, Ariadna|||0000-0002-1648-5589
  • Masanas, Marc|||0000-0002-2249-8554
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Antonelli, Roberta|||0000-0001-6884-7847
  • Soriano, Aroa|||0000-0001-9659-1471
  • Roma, Josep|||0000-0001-7692-6123
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
In recent decades, biomedical research has focused on understanding the functionality of the human translated genome, which represents a minor part of all genetic information transcribed from the human genome. However, researchers have become aware of the importance of non-coding RNA species that constitute the vast majority of the transcriptome. In addition to their crucial role in tissue development and homeostasis, mounting evidence shows non-coding RNA to be deregulated and functionally contributing to the development and progression of different types of human disease including cancer both in adults and children. Small non-coding RNAs (i.e., microRNA) are in the vanguard of clinical research which revealed that RNA could be used as disease biomarkers or new therapeutic targets. Furthermore, many more expectations have been raised for long non-coding RNAs, by far the largest fraction of non-coding transcripts, and still fewer findings have been translated into clinical applications. In this review, we center on PVT1, a large and complex long non-coding RNA that usually confers oncogenic properties on different tumor types. We focus on the compilation of early advances in the field of pediatric tumors which often lags behind clinical improvements in adult tumors, and provide a rationale to continue studying PVT1 as a possible functional contributor to pediatric malignancies and as a potential prognostic marker or therapeutic target.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models

  • Antonelli, Roberta|||0000-0001-6884-7847
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Riley, Misha
  • Servidei, Tiziana|||0000-0003-0529-7686
  • Riccardi, Riccardo
  • Soriano, Aroa|||0000-0001-9659-1471
  • Roma, Josep|||0000-0001-7692-6123
  • Martinez-Saez, Elena|||0000-0001-6004-5364
  • Martini, Maurizio|||0000-0002-6260-6310
  • Ruggiero, Antonio|||0000-0002-6052-3511
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Gallego, Soledad|||0000-0002-4712-9624
  • Bové, Jordi|||0000-0002-2529-205X
  • Hooker, Jacob M.
  • Segura, Miguel F.|||0000-0003-0916-3618
Pediatric ependymoma (EPN) is a highly aggressive tumor of the central nervous system that remains incurable in 40% of cases. In children, the majority of cases develop in the posterior fossa and can be classified into two distinct molecular entities: EPN posterior fossa A (PF-EPN-A) and EPN posterior fossa B (PF-EPN-B). Patients with PF-EPN-A have poor outcome and are in demand of new therapies. In general, PF-EPN-A tumors show a balanced chromosome copy number profile and have no recurrent somatic nucleotide variants. However, these tumors present abundant epigenetic deregulations, thereby suggesting that epigenetic therapies could provide new opportunities for PF-EPN-A patients. In vitro epigenetic drug screening of 11 compounds showed that histone deacetylase inhibitors (HDACi) had the highest anti-proliferative activity in two PF-EPN-A patient-derived cell lines. Further screening of 5 new brain-penetrating HDACi showed that CN133 induced apoptosis in vitro, reduced tumor growth in vivo and significantly extended the survival of mice with orthotopically-implanted EPN tumors by modulation of the unfolded protein response, PI3K/Akt/mTOR signaling, and apoptotic pathways among others. In summary, our results provide solid preclinical evidence for the use of CN133 as a new therapeutic agent against PF-EPN-A tumors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro

  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Antonelli, Roberta|||0000-0001-6884-7847
  • Masanas, Marc|||0000-0002-2249-8554
  • Soriano, Aroa|||0000-0001-9659-1471
  • Devis-Jauregui, Laura|||0000-0003-3736-3983
  • Camacho, Jessica|||0000-0001-8018-8274
  • Magdaleno, Ainara|||0000-0002-2718-3244
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Hladun, Raquel|||0000-0002-3191-1750
  • Jubierre Zapater, Luz
  • Llobet Navas, David|||0000-0003-1443-7003
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
Neuroblastoma is the most common pediatric solid tumor occurring outside the brain, and it is thought to arise from cells that acquire errors during the normal process of embryonal development. Today, we know that embryonal development is regulated by epigenetics, a mechanism that determines which genes need to be expressed in each cell type and developmental step. Epigenetic errors, therefore, are considered contributory to the appearance and progression of tumors such as neuroblastoma. Here, we aimed at finding whether ZRF1, a known epigenetic regulator, could play a significant role in the aggressiveness of neuroblastoma. Our results suggest that ZRF1 does not seem to have any relevant function in neuroblastoma cells; however, the levels of this epigenetic regulator are related to the prognostic of neuroblastoma patients and could be used to predict their progression and improve the diagnosis. Neuroblastoma is a pediatric tumor of the peripheral nervous system that accounts for up to ~15% of all cancer-related deaths in children. Recently, it has become evident that epigenetic deregulation is a relevant event in pediatric tumors such as high-risk neuroblastomas, and a determinant for processes, such as cell differentiation blockade and sustained proliferation, which promote tumor progression and resistance to current therapies. Thus, a better understanding of epigenetic factors implicated in the aggressive behavior of neuroblastoma cells is crucial for the development of better treatments. In this study, we characterized the role of ZRF1, an epigenetic activator recruited to genes involved in the maintenance of the identity of neural progenitors. We combined analysis of patient sample expression datasets with loss- and gain-of-function studies on neuroblastoma cell lines. Functional analyses revealed that ZRF1 is functionally dispensable for those cellular functions related to cell differentiation, proliferation, migration, and invasion, and does not affect the cellular response to chemotherapeutic agents. However, we found that high levels of ZRF1 mRNA expression are associated to shorter overall survival of neuroblastoma patients, even when those patients with the most common molecular alterations used as prognostic factors are removed from the analyses, thereby suggesting that ZRF1 expression could be used as an independent prognostic factor in neuroblastoma.